FDA approves $4.25 million gene therapy for MLD
- Once again, the pharmaceutical industry has topped its existing astronomical prices with Lenmeldy, an FDA-approved gene therapy for children with pre-symptomatic late infantile, pre-symptomatic early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy (MLD), which has a wholesale acquisition price tag of $4.25...
More Articles
Continuous Manufacturing Revolutionizes Pharmaceutical Production
In the pharmaceutical sector, continuous manufacturing (CM) has emerged as a transformative technology with the potential to revolutionize the industry. As drugmakers seek to enhance efficiency, reduce costs, and ensure a resilient supply...Senate Report Exposes Big Pharma’s Profiteering at Americans’ Expense
On February 6, 2024, the United States Senate's Health, Education, Labor, and Pensions (HELP) Committee published a Majority Staff Report highlighting the issue of exorbitant drug prices in the United States. It focuses on the business...Senate Hearing Challenges Pharma CEOs on Drug Pricing
In a heated Senate hearing on February 8th, the CEOs of Bristol Myers Squibb, Johnson & Johnson, and Merck faced rigorous questioning from various United States senators regarding the exorbitant...500 Drugs from Over 140 Brands Are Expected to Cost More This Year
Last week, just before the end of 2023, Reuters published an article breaking a story from data analyzed by 3 Axis Advisors, a healthcare research firm. The analysis evaluated anticipated drug price...Price Transparency Healthcare Policies Reduce Out-Of-Pocket Costs
Price transparency enables patients to shop for the most effective and inexpensive healthcare available and is vital as patient out-of-pocket healthcare costs continue to skyrocket year-over-year. A 2021 Kalorama Information...Exploring Prescription Discount Cards’ Role in Medication Adherence
Since prescription discount cards were introduced into the United States market in the early 2000s, patients and providers have leveraged them to combat rising drug costs and make medications more affordable. By enhancing drug...US States, Cities Sue Insulin Makers Over Shortages, High Prices
In recent weeks, a wave of lawsuits has emerged as more states and cities in the United States take legal action against insulin makers and pharmacy benefit managers (PBMs). These lawsuits allege that...Sponsored by Optum
Controlling Oncology Costs with Cross-Benefit Drug Management
The oncology care landscape is dynamic, shaped by rising cancer medication expenses, medical advancements, and the persistent influence of outside challenges like COVID-19. To navigate this complexity...The Importance of Accurately Measuring the Value of New Medications
Last month, No Patient Left Behind, an American nonprofit organization pushing for healthcare reform in the United States to make drugs more affordable, published a report assessing the accuracy and utility of current cost-effectiveness...Sponsored by Optum
